Overview
Acadia Pharmaceuticals is a biopharmaceutical company commercializing Nuplazid (pimavanserin), the first FDA-approved drug specifically for hallucinations and delusions associated with Parkinson's disease psychosis. They are also developing treatments for Alzheimer's disease psychosis and Rett syndrome.
More in Neuropharmaceuticals
Latest industry news
Closed-Loop BCIs Charted as Next Frontier for Depression, Anxiety, and PTSD Treatment
2026-07-21 · Research
Instruments of Self-Knowledge: How Cognitive Assessment Tech Is Making the Invisible Mind Measurable
2026-07-21 · Industry
Top 10 Technologies Turning Self-Awareness Into Something You Can Actually See
2026-07-21 · Industry
China Clears Brain-Computer Interfaces for Commercial Use, Prompting Calls for Global Regulatory Alignment
2026-07-20 · Policy
Company details
Category
💊 Neuropharmaceuticals
Location
San Diego, USA
Funding
Public · NASDAQ: ACAD
Website
www.acadia-pharm.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →